Your browser doesn't support javascript.
loading
Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells.
Correia, Ricardo; Fernandes, Bárbara; Castro, Rute; Nagaoka, Hikaru; Takashima, Eizo; Tsuboi, Takafumi; Fukushima, Akihisa; Viebig, Nicola K; Depraetere, Hilde; Alves, Paula M; Roldão, António.
Affiliation
  • Correia R; IBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
  • Fernandes B; ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
  • Castro R; IBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
  • Nagaoka H; ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
  • Takashima E; IBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
  • Tsuboi T; Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.
  • Fukushima A; Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.
  • Viebig NK; Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.
  • Depraetere H; Sumitomo Pharma Co., Ltd., Osaka, Japan.
  • Alves PM; European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
  • Roldão A; European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Front Bioeng Biotechnol ; 10: 908509, 2022.
Article in En | MEDLINE | ID: mdl-35845392
ABSTRACT
The malaria asexual blood-stage antigen PfRipr and its most immunogenic fragment PfRipr5 have recently risen as promising vaccine candidates against this infectious disease. Continued development of high-yielding, scalable production platforms is essential to advance the malaria vaccine research. Insect cells have supplied the production of numerous vaccine antigens in a fast and cost-effective manner; improving this platform further could prove key to its wider use. In this study, insect (Sf9 and High Five) and human (HEK293) cell hosts as well as process-optimizing strategies (new baculovirus construct designs and a culture temperature shift to hypothermic conditions) were employed to improve the production of the malaria asexual blood-stage vaccine candidate PfRipr5. Protein expression was maximized using High Five cells at CCI of 2 × 106 cell/mL and MOI of 0.1 pfu/cell (production yield = 0.49 mg/ml), with high-purity PfRipr5 binding to a conformational anti-PfRipr monoclonal antibody known to hold GIA activity and parasite PfRipr staining capacity. Further improvements in the PfRipr5 expression were achieved by designing novel expression vector sequences and performing a culture temperature shift to hypothermic culture conditions. Addition of one alanine (A) amino acid residue adjacent to the signal peptide cleavage site and a glycine-serine linker (GGSGG) between the PfRipr5 sequence and the purification tag (His6) induced a 2.2-fold increase in the expression of secreted PfRipr5 over using the expression vector with none of these additions. Performing a culture temperature shift from the standard 27-22°C at the time of infection improved the PfRipr5 expression by up to 1.7 fold. Notably, a synergistic effect was attained when combining both strategies, enabling to increase production yield post-purification by 5.2 fold, with similar protein quality (i.e., purity and binding to anti-PfRipr monoclonal antibody). This work highlights the potential of insect cells to produce the PfRipr5 malaria vaccine candidate and the importance of optimizing the expression vector and culture conditions to boost the expression of secreted proteins.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Bioeng Biotechnol Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Bioeng Biotechnol Year: 2022 Document type: Article Affiliation country:
...